Salivary Immunoglobulin A,E,and G4 Levels Specific to Dermatophagoides pteronyssinus in Allergic Rhinitis Patients Treated With Subcutaneous Immunotherapy

Abstract

Background

Allergen-specific immunotherapy (AIT) is an effective treatment for allergic rhinitis (AR). During the course of AIT, many biomarkers in body fluids change. It is necessary to find effective indicators of AIT.

Objective

To examine levels of salivary immunoglobulin A, E, and G4 (IgA, IgE, and IgG4, respectively) specific to Dermatophagoides pteronyssinus (Dp-IgA, Dp-IgE, and Dp-IgG4, respectively) and their changes in AR patients undergoing subcutaneous immunotherapy (SCIT).

Methods

This study included 82 patients with AR sensitized only to Dp and 14 healthy controls. Among patients with AR, 30 patients were not treated with specific immunotherapy (group A), while the remainder (n = 52) received house dust mite SCIT in the up-dosing phase (n = 27; group B) or the maintenance treatment phase (n = 25; group C). Dp-IgA, Dp-IgE, and Dp-IgG4 levels in the saliva were measured using the enzyme-linked immunosorbent assay. Clinical symptoms, concomitant medication, and the Rhinoconjunctivitis Quality of Life Questionnaire score were recorded and correlated with immunoglobulin levels.

Results

Salivary Dp-IgG4 and Dp-IgA levels were significantly lower in AR patients than in healthy controls (P < .001 for both), while Dp-IgE levels were significantly higher (P < .001). SCIT resulted in sustained increases in Dp-IgG4 and Dp-IgA in the maintenance phase compared to the up-dosing phase (P < .001 for both), whereas Dp-IgE only increased in the up-dosing phase (P = .004, P < .0125). There was no correlation between the different salivary immunoglobulins and clinical scores during SCIT.

Conclusions

This study shows that allergen-specific IgE levels are increased in the saliva of sensitized patients, suggesting that measuring salivary IgE testing should be further considered for the diagnosis of AR. Moreover, allergen-specific IgA and IgG4 in the saliva, which may play protective roles against allergy, may serve as objective indicators for evaluating treatment response to SCIT. However, none of the immunoglobulin reflects subjective symptoms.

Keywords

allergic rhinitis subcutaneous immunotherapy immunoglobulin saliva quality of life symptom clinical scores

Get full access to this article

View all access options for this article.

References

Small

Frenkiel

Becker

et al . Rhinitis: a practical and comprehensive approach to assessment and therapy. J Otolaryngology. 2007; 36(Suppl 1):527.

Bousquet

Khaltaev

Cruz

et al . Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA (2)LEN and AllerGen). Allergy. 2008; 63(Suppl 86):8–160.

Dykewicz

Hamilos

DL.

Rhinitis and sinusitis.

J Allergy Clin Immunol. 2010; 125(2 Suppl 2):S103–S115.

Wang

Zhang

Sun

Future perspectives of Chinese medical formulae: chinmedomics as an effector.

OMICS. 2012; 16(7–8):414–421.

Aydogan

Mete

Yazi

et al . Comparison of Der p1-specific antibody levels in children with allergic airway disease and healthy controls. Pediatr Allergy Immunol. 2007; 18(4):320–325.

Mimura

Usui

Mori

et al . Immunochromatographic assay for measurement of total IgE in tears, nasal mucus, and saliva of patients with allergic rhinoconjunctivitis. J Asthma. 2010; 47(10):1153–1160.

Grouin

Vicaut

Jean-Alphonse

et al . The average Adjusted Symptom Score, a new primary efficacy end-point for specific allergen immunotherapy trials. Clin Exp Allergy. 2011; 41(9):1282–1288.

Juniper

Thompson

Ferrie

Roberts

JN.

Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire.

J Allergy Clin Immunol. 1999; 104(2 Pt 1):364–369.

Perez-Cornejo

Gokhale

Duran

et al . Anoctamin 1 (Tmem16A) Ca2+-activated chloride channel stoichiometrically interacts with an ezrin–radixin–moesin network. Proc Natl Acad Sci U S A. 2012; 109(26):10376–10381.

10.

Zhang

Sun

Wang

Serum metabolomics as a novel diagnostic approach for disease: a systematic review.

Anal Bioanal Chem. 2012; 404(4):1239–1245.

11.

Brandtzaeg

Induction of secretory immunity and memory at mucosal surfaces.

Vaccine. 2007; 25(30):5467–5484.

12.

Bottcher

Haggstrom

Bjorksten

Jenmalm

MC.

Total and allergen-specific immunoglobulin A levels in saliva in relation to the development of allergy in infants up to 2 years of age.

Clin Exp Allergy. 2002; 32(9):1293–1298.

13.

Fageras

Tomicic

Voor

Bjorksten

Jenmalm

MC.

Slow salivary secretory IgA maturation may relate to low microbial pressure and allergic symptoms in sensitized children.

Pediatr Res. 2011; 70(6):572–577.

14.

Macpherson

McCoy

Johansen

Brandtzaeg

The immune geography of IgA induction and function.

Mucosal Immunol. 2008; 1(1):11–22.

15.

Heystek

Moulon

Woltman

Garonne

van Kooten

Human immature dendritic cells efficiently bind and take up secretory IgA without the induction of maturation.

J Immunol. 2002; 168(1):102–107.

16.

Schwarze

Cieslewicz

Joetham

et al . Antigen-specific immunoglobulin-A prevents increased airway responsiveness and lung eosinophilia after airway challenge in sensitized mice. Am J Respir Crit Care Med. 1998; 158(2):519–525.

17.

Krajewska-Wojtys

Jarzab

Gawlik

Bozek

Local allergic rhinitis to pollens is underdiagnosed in young patients.

Am J Rhinol Allergy. 2016; 30(6):198–201.

18.

Nakajima

Gillespie

Gleich

GJ.

Differences between IgA and IgEas secretory proteins. Clin Exp Immunol. 1975; 21(2):306–317.

19.

Miranda

Silva

Fernandes

et al . Serum and salivary IgE, IgA, and IgG4 antibodies to Dermatophagoides pteronyssinus and its major allergens, Der p1 and Der p2, in allergic and nonallergic children. Clin Dev Immunol. 2011;2011:302739.

20.

Stylianou

Ueland

Borchsenius

et al . Specific allergen immunotherapy: effect on IgE, IgG4 and chemokines in patients with allergic rhinitis. Scand J Clin Lab Invest. 2016; 76(2):118–127.

21.

Pereira

Silva

Cunha-Junior

et al . IgE, IgG1, and IgG4 antibody responses to Blomia tropicalis in atopic patients. Allergy. 2005; 60(3):401–406.

22.

Mori

Pires

Galvao

Ferreira de Mello

Golcher

Montealegre

Determination of Blomia tropicalis-specific IgE and IgG subclasses in atopic dermatitis patients.

Allergy. 2001; 56(2):180–184.

23.

Wachholz

Durham

SR.

Mechanisms of immunotherapy: IgG revisited.

Curr Opin Allergy Clin Immunol. 2004; 4(4):313–318.

24.

Schmid

Wurtzen

Dahl

Hoffmann

HJ.

Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy.

J Allergy Clin Immunol. 2014; 134(3):741–744 e745.

25.

Lalek

Kosnik

Silar

Korosec

Immunoglobulin G-dependent changes in basophil allergen threshold sensitivity during birch pollen immunotherapy.

Clin Exp Allergy. 2010; 40(8):1186–1193.

26.

Matsuoka

Shamji

Durham

SR.

Allergen immunotherapy and tolerance.

Allergol Int. 2013; 62(4):403–413.

27.

Feng

Lai

et al . Functional and immunoreactive levels of IgG4 correlate with clinical responses during the maintenance phase of house dust mite immunotherapy. J Immunol. 2018; 200(12):3897–3904.

28.

Van Metre

Jr Adkinson

Jr Lichtenstein

et al . A controlled study of the effectiveness of the Rinkel method of immunotherapy for ragweed pollen hay fever. J Allergy Clin Immunol. 1980; 65(4):288–297.

29.

Xiao

Wang

Cui

Lai

Gjesing

Spangfort

Zhong

The effect on Der f specific IgG4 of mite allergic patient after Der p specific immunotherapy (in Chinese). Chin J Allergy Clin Immunol. 2009; 3:34–38.

30.

Tahamiler

Canakcioglu

Yilmaz

Isildak

Long-term immunotherapy for perennial allergic rhinitis: relationship of specific IgG levels to skin-prick test results and clinical symptoms and signs.

Ear Nose Throat J. 2008; 87(12):E29.

31.

Jutel

Kosowska

Smolinska

Allergen immunotherapy: past, present, and future.

Allergy Asthma Immunol Res. 2016; 8(3):191–197.